Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1/2 16Phase 3 12Phase 1 8Phase 2/3 3Phase NA 1Phase 4 1

Status

Recruiting 3Unknown 2Withdrawn 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Albumin-Bound Paclitaxel × Clear all
NCT07076121 2026-04-30

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06037980 2025-02-17

PURITY

Gruppo Oncologico del Nord-Ovest

Phase 2/3 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05254171 2024-11-06

ASPIRE

Panbela Therapeutics, Inc.

Phase 2/3 Recruiting
600 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡